Director’s Corner Podcast: Drug Compounding
The Director’s Corner is an audio podcast series featuring Dr. Woodcock, Director of FDA’s Center for Drug Evaluation and Research (CDER), and produced by CDER’s Office of Communications. In the latest podcast,Dr. Woodcock discusses Drug Compounding from both a safety and regulatory standpoint and addresses the following questions:
- What is pharmacy compounding and can you provide some examples?
- What are some of the regulatory and safety concerns relating specifically to compounding?
- What is FDA doing to address the safety concerns?
- Why it is important that drug compounding remain an option for the healthcare system?
We hope that you are able to tune in!
The CDER SBIA team
The Small Business and Industry Assistance program in the Center for Drug Evaluation and Research (CDER SBIA) provides guidance and information to regulated domestic and international small pharmaceutical business and industry through its website, email notifications, and workshops. This notification system provides current information from CDER/FDA via e-mail on a biweekly basis that is relevant to small pharmaceutical business, which includes Federal Register notices, guidances, workshop announcements, etc. This is an automated message delivery system. Replying to this message will not reach the CDER SBIA staff. If you have comments or questions, please contact us Monday through Friday 8:00AM - 4:30PM.
- Email: CDERSBIA@fda.hhs.gov
- Phone: 1-866-405-5367
- Phone: (301) 796-6707
- Website: http://www.fda.gov/cdersbia
Please take our CDER SBIA survey: https://www.surveymonkey.com/
.png)
No hay comentarios:
Publicar un comentario